DOCSLIB.ORG

Bovine Factor X1 (Stuart Factor). Primary Structure of the Light Chain (Amino-Acid Sequence/Blood Coagulation) DAVID L

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bovine Factor X1 (Stuart Factor). Primary Structure of the Light Chain (Amino-Acid Sequence/Blood Coagulation) DAVID L Proc. Nat. Acad. Sci. USA Vol. 72, No. 1, pp. 16-19, January 1975 Bovine Factor X1 (Stuart Factor). Primary Structure of the Light Chain (amino-acid sequence/blood coagulation) DAVID L. ENFIELD, LOWELL H. ERICSSON, KENNETH A. WALSH, HANS NEURATH, AND KOITI TITANI Department of Biochemistry, University of Washington, Seattle, Wash. 98195 Contributed by Hans Neurath, October 21, 1974 ABSTRACT The amino-acid sequence of the light and on five large fragments prepared as shown diagrammati- chain of bovine factor X1 is presented. The sequence of 112 cally in Fig. 1. Two fragments were obtained by cleavage of of the 140 residues was determined automatically on fragments produced by specific cleavage of arginyl, glu- asparaginyl-glycine bonds (10) and one fragment each by tamyl, tryptophanyl, and asparaginyl-glycine bonds. The cleavage of peptide bonds adjacent to tryptophanyl (11) and remainder was determined by conventional procedures. glutamyl (12) residues. The fifth fragment was isolated after a The amino-terminal sequence of the light chain is homol- cleavage adjacent to arginyl residues, requiring succinylation ogous with the amino-terminal region of bovine prothrom- and blocking of free carboxyl groups bin and, like the latter, appears to contain several residues of E-amino groups (13) of a recently discovered unusual amino acid, -y-carboxy- with glycinamide (14, 15). These sequenator analyses pro- glutamic acid. The role of this amino acid in the calcium- vided the sequence of 112 residues. The sequences of the re- binding ability of factor X and prothrombin is discussed. maining residues were determined by conventional Edman degradation techniques (16, 17), using tryptic, chymotryptic, Bovine factor X (Stuart factor) is the zymogen of a protease -and by digestion with activation is me- peptic, and thermolytic peptides, involved in blood coagulation. Zymogen carboxypeptidases A and B. diated by activated factor IX (factor IXa), in the presence of Amino-acid analyses were performed on Beckman (model factor VIII, calcium, and phospholipid, as well as by Russell's 120C) and Durrum (model D-500) amino-acid analyzers. viper venom and by trypsin (1-3). Activated factor X (factor as (13). thrombin. Half-cystine was determined S-pyridylethylcysteine Xa) catalyzes the conversion of prothrombin to Amide sidecha1*s were identified after digestion with amino- Purified bovine factor X can be separated chromatograph- electrophoresis at pH similar peptidase M (18' or by high voltage ically into two fractions (factors XI and X2) having 6.5. chemical and biological properties (4, 5). As commonly de- scribed, factor X is a glycoprotein of molecular weight 54,000, RESULTS containing about 10% carbohydrate and composed of two The amino-acid sequence of the light chain of bovine factor polypeptide chains linked by one or more disulfide bonds Xi is shown in Fig. 2. The amino-acid compositions, as deter- (4, 6). The light and heavy chains have molecular weights of mined by analysis and as calculated from the sequence, are 16,000 and 38,000, respectively; the carbohydrate is exclu- compared in Table 1. The agreement is good except for a dis- sively associated with the heavy chain. crepancy in aspartic acid content. The heavy chains of bovine factors X5 and IXa are homol- Sequenator analysis A (Fig. 1) yielded the first 40 amino- ogous with trypsin, thrombin, and other mammalian serine terminal residues of the intact protein, except for residues 32, proteases (7, 8). The homology is particularly apparent in the 35, 36, and 39. The aspartic acid at position 38 must be con- amino-terminal regions and in the peptide segments sur- sidered tentative because considerable overlap from the pre- rounding the serine residue of the active site. Furthermore, vious step normally occurs after multiple consecutive deg- the amino-terminal sequences of the zymogens, factor IX and radations, and one of the peaks characteristic of threonine on prothrombin, and of the light chain of factor X are also the gas chromatograph coincides with that representing homologous (9). These homologies suggest that these three aspartic acid (19). In addition, all of the glutamic-acid resi- serine proteases involved in blood coagulation and the pan- dues identified within the first 30 amino-terminal residues creatic serine proteases have evolved from a common an- were observed at lower levels than expected. This was espe- cestral gene. For this reason, and in order to establish a basis cially striking at positions 6 and 7, but became less marked in for relating the chemical structure of factor Xa to its func- subsequent degradation steps. tion, the determination of its amino-acid sequence was under- When the light chain was subjected to chymotryptic di- taken. This communication presents a preliminary account gestion, a large "core" peptide derived from the amino- of the sequence of the light chain. terminal region of the molecule remained undigested and could be isolated by precipitation at pH 4. (The term "core" is METHODS intended to imply nothing more than resistance to proteol- Purified bovine factor X, was isolated from bovine plasma (4) ysis.) The amino-terminal sequence of the "core" is Alar- by Dr. Kazuo Fujikawa. The protein was reduced and py- Asn-Ser-Phe, and its amino-acid composition (Table 1) cor- ridylethylated, and the two chains were separated as de- responds to residues 1-44 in the sequence, if residues 32, 35, scribed (4). 36, and 39 are each either glutamic acid or glutamine. Anal- Automatic sequence analysis was performed with the ysis B, beginning with ?-Vala0-Phe-?, was extended to 12 turns Beckman Sequencer (model 890B) on the intact light chain on a fragment obtained by specific tryptic cleavage of arginyl 16 Downloaded by guest on September 24, 2021 Proc. Nat. Acad. Sci. USA 72 (1975) Primary Structure of Factor X1 17 Arg Asn A Arg Trp Glu Asn 5 10 15 V777777=77-T.~l 28 41 51 63 86 93 Ala Asn Ser Phe Leu Glut Glut Val Lys Gin Gly Asn Leu Glut Arg Leu Giu* Ala Val SOURCES OF FRAGMENTS 16 Glu' Cys Leu Glut Glu- Ala Cys Ser Glut Arg Glut 31 Phe Glu* Asp Ala Glu* Gin Thr Asp* Gin' Phe Trp Ser Lys Tyr Lys I. Cleavage at Arginines 28 and 86 after Carboxyl Glu His Pro Leu Asn Gin Gly His Group Modification. 46 Asp Gly Asp Gin Cys Gly Cys Thr Thr Ala Glu B 61 Cys Lys Asn Gly Ile Gly Asp Tyr Cys Cys Gly 76 Phe Glu Gly Lys Asn Cys Glu Phe Ser Thr Arg Glu Ile Cys Ser 91 Leu Asp Asn Gly Gly Cys Asp Gin Phe Cys Arg Glu Glu Arg Ser II. Cleavage at Tryptophan 41 106 Glu Val Arg Cys Ser Cys Ala His Gly Tyr Val Leu Gly Asp Asp C 121 Ser Lys Ser Cys Val Ser Thr Glu Arg Phe Pro Cys Gly Lys Phe 136 Thr Gin Gly Arg Ser FIG. 2. The amino-acid sequence of the light chain of bovine l. Cleavage at Glutamic Acid 51 factor Xi. Asterisks (*) indicate tentative identifications (see D text). Hyphens between residues have been omitted. JZ. Cleavage at Asporaginyl-Glycines 63-64and 93-94 fragment beginning with the amino-terminal sequence of the E F light chain and two additional fragments. The smaller of these yielded the sequence of 25 residues (analysis E) beginning with SUMMARY OF SEQUENATOR ANALYSES Gly64-le-Gly-Asp, which placed this fragment by overlap A with analysis D. The other fragment, consisting of the car- B boxyl portion of the light chain, yielded the sequence of 29 residues (analysis F) beginning with Gly94-Gly-Cys-Asp. The E sequences of residues 89-94 and 122-140 were completed by F conventional techniques on tryptic, chymotryptic, and ther- molytic peptides. FIG. 1. Diagrammatic summary of fragments generated from the light chain of factor XI for sequenator analysis. The top bar TABLE 1. Amino-acid composition of the light chain represents the light chain and the residues that are important for of bovine factor Xi and of the chymotryptic and peptic its fragmentation. The capital letters, A-F, identify the sequen- "core" peptides* ator analyses in the order in which they are described in the text. The hatched section of each horizontal bar indicates the segment Found Chymo- of sequence determined by that analysis. The overlaps among Light in tryptic Peptic these segments are illustrated by the arrows in the lower portion Amino acid chaint sequence "core"$ "core"§ of the figure. Aspartic acid 14 15 4 4 bonds after all free carboxyl groups were modified with gly- Threonine 6 6 1 1 cinamide. The phenylthiohydantoins of the aspartic and Serine 11 11 3 2 glutamic-acid residues modified in this manner could not be Glutamic acid 27 27 14 14 identified in the gas chromatograph, but, assuming that all Proline 2 2 14 1 1 blank positions involve acidic residues, the results are con- Glycine 14 6 6 4 4 sequence given in Fig. 2. This region of the Alanine sistent with the 2 of the Half-cystine 15 15 2 sequence is being investigated further. Subdigestion Valine 5 5 2 2 chymotryptic "core" with pepsin yielded another "core," cor- Isoleucine 2 2 responding in composition to residues 1-40 (see Table 1), as Leucine 7 7 4 4 well as free tryptophan and two small peptides, i.e., Trp41- Tyrosine 3 3 1 Ser-Lys-Tyr and Ser42-Lys-Tyr. These results established the Phenylalanine 8 8 3 3 carboxyl-terminal sequence of the chymotryptic "core" pep- Lysine 7 7 2 1 tide. Histidine 3 3 In order to extend the sequence beyond the "core" region, Arginine 8 8 2 2 cleavage adjacent to the tryptophanyl residue was used.
Load more

Recommended publications
  • PRSS1 Gene Serine Protease 1
    PRSS1 gene serine protease 1 Normal Function The PRSS1 gene provides instructions for making an enzyme called cationic trypsinogen. This enzyme is a serine peptidase, which is a type of enzyme that cuts ( cleaves) other proteins into smaller pieces. Cationic trypsinogen is produced in the pancreas and helps with the digestion of food. Cationic trypsinogen is secreted by the pancreas and transported to the small intestine, where it is cleaved to form trypsinogen. When the enzyme is needed, trypsinogen is cleaved again into its working (active) form called trypsin. Trypsin aids in digestion by cutting protein chains at the protein building blocks (amino acids) arginine or lysine, which breaks down the protein. Trypsin also turns on (activates) other digestive enzymes that are produced in the pancreas to further facilitate digestion. A particular region of trypsin is attached (bound) to a calcium molecule. As long as trypsin is bound to calcium, the enzyme is protected from being broken down. When digestion is complete and trypsin is no longer needed, the calcium molecule is removed from the enzyme, which allows trypsin to be broken down. Health Conditions Related to Genetic Changes Hereditary pancreatitis More than 40 mutations in the PRSS1 gene have been found to cause hereditary pancreatitis, a condition characterized by recurrent episodes of inflammation of the pancreas (pancreatitis), which can lead to a loss of pancreatic function. Most of these mutations change single protein building blocks (amino acids) in cationic trypsinogen. Some PRSS1 gene mutations result in the production of a cationic trypsinogen enzyme that is prematurely converted to trypsin while it is still in the pancreas.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Functional Prediction and Comparative Population Analysis of Variants in Genes for Proteases and Innate Immunity Related to SARS
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.093690; this version posted May 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection Kristel Klaassen1¶, Biljana Stankovic1¶, Branka Zukic1, Nikola Kotur1, Vladimir Gasic1, Sonja Pavlovic1, Maja Stojiljkovic1* 1Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia * Corresponding author E-mail: [email protected] (MS) ¶These authors contributed equally to this work. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.093690; this version posted May 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract New coronavirus SARS-CoV-2 is capable to infect humans and cause a novel disease COVID-19. Aiming to understand a host genetic component of COVID-19, we focused on variants in genes encoding proteases and genes involved in innate immunity that could be important for susceptibility and resistance to SARS-CoV-2 infection. Analysis of sequence data of coding regions of FURIN, PLG, PRSS1, TMPRSS11a, MBL2 and OAS1 genes in 143 unrelated individuals from Serbian population identified 22 variants with potential functional effect.
    [Show full text]
  • Page 1 of 76 Diabetes Diabetes Publish Ahead of Print, Published Online September 14, 2020
    Page 1 of 76 Diabetes Peters, Annette; Helmholtz Center Munich German Research Center for Environmental Health, Epidemiology Institute Waldenberger, Melanie; Helmholtz Center Munich German Research Center for Environmental Health, Molecular Epidemiology Diabetes Publish Ahead of Print, published online September 14, 2020 Diabetes Page 2 of 76 Deciphering the Plasma Proteome of Type 2 Diabetes Mohamed A. Elhadad1,2,3 MSc., Christian Jonasson4,5 PhD, Cornelia Huth2,6 PhD, Rory Wilson1,2 MSc, Christian Gieger1,2,6 PhD, Pamela Matias1,2,3 MSc, Harald Grallert1,2,6 PhD, Johannes Graumann7,8 PhD, Valerie Gailus-Durner9 PhD, Wolfgang Rathmann6,10 MD, Christine von Toerne11 PhD, Stefanie M. Hauck11 PhD, Wolfgang Koenig3,12,13 MD, FRCP, FESC, FACC, FAHA, Moritz F. Sinner3,14 MD, MPH, Tudor I Oprea15,16,17 MD, PhD, Karsten Suhre18 PhD, Barbara Thorand2,6 PhD, Kristian Hveem4,5 PhD, Annette Peters2,3,6,19 PhD, Melanie Waldenberger1,2,3 PhD 1. Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. 2. Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany 3. German Research Center for Cardiovascular Disease (DZHK), Partner site Munich Heart Alliance, Germany 4. K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health, NTNU - Norwegian University of Science and Technology, Trondheim, Norway 5. HUNT Research Center, Department of Public Health, NTNU - Norwegian University of Science and Technology, Levanger, Norway 6. German Center for Diabetes Research (DZD), München-Neuherberg, Ingolstädter Landstr. 1, 85764, Neuherberg, Germany 7. Biomolecular Mass Spectrometry, Max Planck Institute for Heart and Lung Research, Ludwigstrasse 43, Bad Nauheim 61231, Germany 8.
    [Show full text]
  • Aspartyl F3-Hydroxylase: in Vitro Hydroxylation of a Synthetic
    Proc. Nadl. Acad. Sci. USA Vol. 86, pp. 3609-3613, May 1989 Biochemistry Aspartyl f3-hydroxylase: In vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX (epidermal growth factor-like domain/f3-hydroxyaspartic acid) ROBERT S. GRONKE*, WILLIAM J. VANDUSEN*, VICTOR M. GARSKYt, JOHN W. JACOBSt, MOHINDER K. SARDANAt, ANDREW M. STERN*, AND PAUL A. FRIEDMAN*§ Departments of *Pharmacology, tMedicinal Chemistry, and tBiological Chemistry, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486 Communicated by Edward M. Scolnick, February 17, 1989 ABSTRACT .3-Hydroxylation of aspartic acid is a post- (16) either with heavy metal chelators such as 2,2'-dipyridyl translational modification that occurs in several vitamin K- (dipy) or with 2,4-pyridine dicarboxylate, an analogue of dependent coagulation proteins. By use of a synthetic substrate 2-ketoglutarate (KG) known to block proline hydroxylase comprised of the first epidermal growth factor-like domain in (17), our initial experiments with EGF-IX1H used experimen- human factor IX and either mouse L-cell extracts or rat liver tal conditions favorable for KG dioxygenases such as prolyl microsomes as the source of enzyme, in vitro aspartyl 13- or lysyl hydroxylase (18). We report here in vitro demon- hydroxylation was accomplished. Aspartyl f3-hydroxylase ap- stration of .8-hydroxylation of Asp residues and show that pears to require the same cofactors as known a-ketoglutarate- this enzymatic activity requires both Fe2' and KG. dependent dioxygenases. The hydroxylation reaction proceeds with the same stereospecificity and occurs only at the aspartate corresponding to the position seen in vivo.
    [Show full text]
  • Protease Activated Receptors: Theme and Variations
    Oncogene (2001) 20, 1570 ± 1581 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Protease activated receptors: theme and variations Peter J O'Brien1,2,3,5, Marina Molino4, Mark Kahn1,2,3,6 and Lawrence F Brass*,1,2,3,7 1Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, PA 19104, USA; 2Department of Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania, PA 19104, USA; 3Center for Experimental Therapeutics at the University of Pennsylvania, Philadelphia, Pennsylvania, PA 19104, USA; 4Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy The four PAR family members are G protein coupled bers, and eorts to identify additional, biologically- receptors that are normally activated by proteolytic relevant proteases that can activate PAR family exposure of an occult tethered ligand. Three of the members. family members are thrombin receptors. The fourth (PAR2) is not activated by thrombin, but can be activated by other proteases, including trypsin, tryptase The current PAR family members and Factor Xa. This review focuses on recent informa- tion about the manner in which signaling through these Four PAR family members have been identi®ed to receptors is initiated and terminated, including evidence date. Three (PAR1, PAR3 and PAR4) are thrombin for inter- as well as intramolecular modes of activation, receptors. The fourth, PAR2, is activated by serine and continuing eorts to identify additional, biologically- proteases other than thrombin (Table 1). PAR1 was relevant proteases that can activate PAR family initially identi®ed using RNA derived from thrombin- members. Oncogene (2001) 20, 1570 ± 1581.
    [Show full text]
  • Identification and Characterization of a Serpin from Eimeria Acervulina
    J. Parasitol., 94(6), 2008, pp. 1269–1274 ᭧ American Society of Parasitologists 2008 IDENTIFICATION AND CHARACTERIZATION OF A SERPIN FROM EIMERIA ACERVULINA R. H. Fetterer, K. B. Miska, M. C. Jenkins, R. C. Barfield, and H. Lillehoj Animal Parasitic Diseases Laboratory, Animal and Natural Resources Institute, U.S. Department of Agriculture, Henry A. Wallace Beltsville Agricultural Research Center, Beltsville, Maryland 20705. e-mail: [email protected] ABSTRACT: Serpins are serine protease inhibitors that are widely distributed in metazoans, but they have not been characterized previously in Eimeria spp. A serpin from Eimeria acervulina was cloned, expressed, and characterized. Random screening of an E. acervulina sporozoite cDNA library identified a single clone (D14) whose coding region shared high similarity to consensus structure of serpins. Clone D14 contained an entire open reading frame consisting of 1,245 nucleotides that encode a peptide of 413 amino acids, with a predicted molecular weight of 45.5 kDa and containing a signal peptide 28 residues. By Western blot analysis, polyclonal antiserum to the recombinant serpin (rbSp) recognized a major 55-kDa protein band in unsporulated oocysts and in oocysts sporulated up to 24 hr (fully sporulated). The anti-rbSp detected bands of 55 and 48 kDa in sporozoites (SZ) and merozoites (MZ), respectively. Analysis of MZ secretion products revealed a single protein of 48 kDa that may correspond to secreted serpin. By immunostaining, the serpin was located in granules distributed throughout both the SZ and MZ, but granules seemed to be concentrated in the parasites’ anterior. Analysis of the structure predicts that the E.
    [Show full text]
  • Trypsin (D-1): Sc-137077
    SANTA CRUZ BIOTECHNOLOGY, INC. Trypsin (D-1): sc-137077 BACKGROUND STORAGE The human pancreas secretes three different isoforms of the inactive trypsino- Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of gen into the small intestine, namely cationic trypsinogen, anionic trypsinogen shipment. Non-hazardous. No MSDS required. (the two major isoforms) and mesotrypsinogen (a minor isoform). In the small intestine, each isoform is cleaved by Enterokinase into its active form, DATA Trypsin-1, Trypsin-2 and Trypsin-3, respectively. All trypsins are members of the serine protease Trypsin family. The activated trypsins go on to activate A B 132 K – other protease zymogens and play a role in the autoactivation of trypsinogens. 90 K – This suggests an important role for trypsins in digestion. Mutations in the 55 K – gene encoding Trypsin-1 that stimulate its activity are associated with auto- 43 K – somal dominant hereditary pancreatitis (HCP), also known as chronic pancre- 34 K – Trypsin atitis (CP), a disease characterized by persistent, severe abdominal pain due 23 K – to calcifications of the parenchyma, pancreatic stones, cysts and pancreatic head enlargement. Trypsin-3 is expressed in the brain in addition to the pancreas. Trypsin (D-1) Alexa Fluor® 647: sc-137077 AF647. Direct Trypsin (D-1) HRP: sc-137077 HRP. Direct immunoperoxi- fluorescent western blot analysis of Trypsin expression dase staining of formalin fixed, paraffin-embedded in rat pancreas tissue extract. Blocked with UltraCruz® human pancreas tissue showing cytoplasmic staining of CHROMOSOMAL LOCATION Blocking Reagent: sc-516214. Cruz Marker™ Molecular exocrine glandular cells. Blocked with 0.25X UltraCruz® Weight Standards detected with Cruz Marker™ MW Blocking Reagent: sc-516214 (A).
    [Show full text]
  • Plasminogen Tochigi: Inactive Plasmin Resulting from Replacement
    Proc. NatL Acad. Sci. USA Vol. 79, pp. 6132-6136, October 1982 Biochemistry Plasminogen Tochigi: Inactive plasmin resulting from replacement of alanine-600 by threonine in the active site (serine proteinase/molecular abnormality/thrombosis) ToSHIYUKI MIYATA*, SADAAKI IWANAGA*t, YoICHI SAKATAt, AND NOBUO AOKIt *Department of Biology, Faculty of Science, Kyushu University 33, Fukuoka 812, Japan; and tInstitute of Hematology and Department of Medicine, Jichi Medical School, Yakushiji, Tochigi-ken 329-04, Japan Communicated by K. M. Brinkhous, June 21, 1982 ABSTRACT Structural studies on a hereditarily abnormal is adsorbed on a lysine-Sepharose column, suggesting that its plasminogen, plasminogen Tochigi, have been performed to iden- lysine-binding sites are intact and functional. These results sug- tify the difference responsible for its lack of proteolytic activity. gest that the abnormality resides at the active site of the mol- The plasminogen sample used was from a heterozygote and thus ecule. The present work was undertaken to elucidate the consisted of apparently equal amounts of normal and defective structural abnormality ofplasminogen Tochigi that explains the plasminogen molecules. Amino acid. sequence analysis of a tryptic functional impairment ofthe molecule. The results indicate that peptide isolated from, the abnormal plasminogen indicated that. the absence ofproteolytic activity is due to replacement ofAla- Ala-600 (equivalent to Ala-55 in the chymotrypsin numbering sys- 600 by Thr in the abnormal plasminogen molecule. We know tem) had been replaced by Thr. No other substitutions in the ac- ofno other example ofa molecular defect in a serine proteinase tive-site residues-namely, His-57, Asp-102, and Ser-195-were due an acid substitution near the active site.
    [Show full text]
  • A Genomic Analysis of Rat Proteases and Protease Inhibitors
    A genomic analysis of rat proteases and protease inhibitors Xose S. Puente and Carlos López-Otín Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, 33006-Oviedo, Spain Send correspondence to: Carlos López-Otín Departamento de Bioquímica y Biología Molecular Facultad de Medicina, Universidad de Oviedo 33006 Oviedo-SPAIN Tel. 34-985-104201; Fax: 34-985-103564 E-mail: [email protected] Proteases perform fundamental roles in multiple biological processes and are associated with a growing number of pathological conditions that involve abnormal or deficient functions of these enzymes. The availability of the rat genome sequence has opened the possibility to perform a global analysis of the complete protease repertoire or degradome of this model organism. The rat degradome consists of at least 626 proteases and homologs, which are distributed into five catalytic classes: 24 aspartic, 160 cysteine, 192 metallo, 221 serine, and 29 threonine proteases. Overall, this distribution is similar to that of the mouse degradome, but significatively more complex than that corresponding to the human degradome composed of 561 proteases and homologs. This increased complexity of the rat protease complement mainly derives from the expansion of several gene families including placental cathepsins, testases, kallikreins and hematopoietic serine proteases, involved in reproductive or immunological functions. These protease families have also evolved differently in the rat and mouse genomes and may contribute to explain some functional differences between these two closely related species. Likewise, genomic analysis of rat protease inhibitors has shown some differences with the mouse protease inhibitor complement and the marked expansion of families of cysteine and serine protease inhibitors in rat and mouse with respect to human.
    [Show full text]
  • Treatment with Exogenous Trypsin Expands in Vitro Cellular Tropism of the Avian Coronavirus Infectious Bronchitis Virus
    viruses Article Treatment with Exogenous Trypsin Expands In Vitro Cellular Tropism of the Avian Coronavirus Infectious Bronchitis Virus Phoebe Stevenson-Leggett , Sarah Keep and Erica Bickerton * The Pirbright Institute, Ash Road, Woking, Surrey GU24 0NF, UK; [email protected] (P.S.-L.); [email protected] (S.K.) * Correspondence: [email protected] Received: 5 August 2020; Accepted: 28 September 2020; Published: 29 September 2020 Abstract: The Gammacoronavirus infectious bronchitis virus (IBV) causes a highly contagious and economically important respiratory disease in poultry. In the laboratory, most IBV strains are restricted to replication in ex vivo organ cultures or in ovo and do not replicate in cell culture, making the study of their basic virology difficult. Entry of IBV into cells is facilitated by the large glycoprotein on the surface of the virion, the spike (S) protein, comprised of S1 and S2 subunits. Previous research showed that the S20 cleavage site is responsible for the extended tropism of the IBV Beaudette strain. This study aims to investigate whether protease treatment can extend the tropism of other IBV strains. Here we demonstrate that the addition of exogenous trypsin during IBV propagation in cell culture results in significantly increased viral titres. Using a panel of IBV strains, exhibiting varied tropisms, the effects of spike cleavage on entry and replication were assessed by serial passage cell culture in the presence of trypsin. Replication could be maintained over serial passages, indicating that the addition of exogenous protease is sufficient to overcome the barrier to infection. Mutations were identified in both S1 and S2 subunits following serial passage in cell culture.
    [Show full text]
  • Effects of Neutrophil Elastase and Other Proteases on Porcine Aortic
    Effects of neutrophil elastase and other proteases on porcine aortic endothelial prostaglandin I2 production, adenine nucleotide release, and responses to vasoactive agents. E C LeRoy, … , A Ager, J L Gordon J Clin Invest. 1984;74(3):1003-1010. https://doi.org/10.1172/JCI111467. Research Article The effects of neutrophil elastase on endothelial prostacyclin (PGI2) production, nucleotide release, and responsiveness to vasoactive agents were compared with the effects of cathepsin G (the other major neutral protease of neutrophils), pancreatic elastase, trypsin, chymotrypsin, and thrombin. PGI2 production by pig aortic endothelial cells cultured on microcarrier beads and perfused in columns was stimulated in a dose-dependent manner by trypsin, chymotrypsin, and cathepsin G (1-100 micrograms/ml for 3 min). Thrombin, while active at low concentrations (0.1-10 National Institutes of Health U/ml), induced smaller responses. Neutrophil and pancreatic elastase had little or no effect on PGI2 production. Dose-dependent, selective release of adenine nucleotides was induced by neutrophil elastase (3-30 micrograms/ml). The other proteases were much less active; for example, trypsin (100 micrograms/ml) induced a response only approximately 5% as great as did 30 micrograms/ml neutrophil elastase. After exposure to 30 micrograms/ml neutrophil elastase, cells did not exhibit the characteristic burst of PGI2 production in response to extracellular ATP; responsiveness gradually returned after 40-120 min. This effect was not seen with the other proteases. Elastase partly inhibited responses to bradykinin and had no effect on PGI2 production that was stimulated by ionophore A23187. There was no evidence of cytotoxicity, as measured by release of lactate dehydrogenase.
    [Show full text]